Codryl

Quick links to important sections

Codryl

Method of action: Antitussive

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Codryl

Property Description
Active ingredients Diphenhydramine hydrochloride, Ammonium chloride
Form Oral Liquid (Syrup or Solution)
Pharmacological Class Antihistamine-Expectorant Combination
Common Purpose Symptomatic relief of cough and cold discomfort
Origin Synthetic compound and inorganic salt

Defining Codryl: Combination Medicine and Pharmacological Class

Codryl is an oral liquid, typically formulated as a syrup or solution, classified as an Antihistamine-Expectorant combination medicine. This preparation is a fixed-dose combination product commonly purchased as an over-the-counter (OTC) remedy for the symptomatic relief of discomfort associated with upper respiratory conditions and the common cold. Its dual classification means it delivers two distinct types of relief simultaneously, distinguishing it from single-ingredient treatments.


Active Ingredients: Diphenhydramine and Ammonium Chloride

The composition of Codryl includes the active ingredients Diphenhydramine hydrochloride and Ammonium chloride. Diphenhydramine is a synthetic compound categorized as a first-generation histamine antagonist. This class of medicine is clinically recognized for its ability to block the effects of histamine. In this formulation, the ingredient is used to provide relief from sneezing, runny nose, and watery eyes.

The second component, Ammonium chloride, is an inorganic salt included primarily for its function as an expectorant. These active components are dissolved in an aqueous or syrupy vehicle, a formulation specifically chosen for stability and suitability for oral consumption.


Dual Action: Antitussive and Expectorant Purpose

The general purpose of Codryl is to mitigate both the irritating cough reflex and the difficulty in clearing thick respiratory secretions. This is achieved because the Diphenhydramine component acts as an antitussive (cough suppressant), helping to quiet the urge for a persistent, dry cough, while the Ammonium chloride component functions as an expectorant. This combination is designed to improve respiratory comfort by both suppressing the irritating cough and facilitating the clearance of secretions.

Regulatory References

  1. NIH MedlinePlus Drug Information

What side effects are possible with Codryl?

Official Documentation of Side Effects and Safety Characteristics

The safety profile of Codryl, a combination of Diphenhydramine and Ammonium Chloride, is established through government regulatory documents and is often structured by frequency classification and System-Organ-Class (SOC) groupings.

Frequency-Classified Adverse Reactions

The most frequent adverse reaction documented in official labeling is drowsiness or sedation, which is often classified as Very Common. Other effects classified as Common include dizziness, disturbed attention, and anticholinergic effects such as dry mouth and constipation.

Adverse Reactions by System-Organ Class (SOC)
Nervous System Disorders: Sedation, Dizziness, Headache, Excitation/Paradoxical reactions.
Gastrointestinal Disorders: Dry mouth, Constipation, Nausea, Vomiting.
Cardiac and Vascular: Tachycardia, Hypotension, Arrhythmias.
Renal and Urinary Disorders: Urinary retention.

Serious Adverse Reactions and Safety Constraints

Regulatory documents specify rare but clinically significant adverse reactions, including severe hypersensitivity reactions and serious hematologic disorders such as agranulocytosis. The label also notes the potential for convulsions and significant cardiac arrhythmias.

Safety constraints are documented for specific populations and pre-existing conditions. Older adults may have increased susceptibility to effects like sedation and hypotension. Constraints related to the drug's anticholinergic action apply to patients with underlying conditions such as narrow-angle glaucoma, prostatic hypertrophy, or bladder neck obstruction. Furthermore, use is constrained in the presence of severe hepatic or renal impairment. Sedative effects are typically most prominent at the initiation of treatment, and concurrent use with other central nervous system depressants or alcohol may result in additive effects.

Overdose and Emergency Response

Overdose Scope

Feature Official Regulatory Documentation
Documented overdose presentations Manifestations include CNS depression (drowsiness, respiratory depression) and CNS excitation (hallucinations, seizures, tremors). Anticholinergic signs like dilated pupils, fever, and urinary retention are also documented.
Physiological systems affected Central Nervous System, Cardiovascular System, Renal/Urinary System.
Dose-related factors Serious outcomes, including coma and death, are officially warned following ingestion of higher than recommended doses.
Population-specific notes CNS excitation is particularly likely in children. Elderly patients are more likely to experience dizziness, sedation, and hypotension in the event of overdose.
Emergency-response statements Management is symptomatic and supportive and may include procedures such as activated charcoal administration and gastric lavage.
When immediate medical help is required Seek immediate medical attention or contact emergency services immediately if the patient is hallucinating, experiences a seizure, has trouble breathing, or has collapsed.

Overdose Classifications (High-Level)

Classification Official Regulatory Documentation
Severity classification Classified as potentially leading to severe or life-threatening outcomes, including arrhythmias and cardiac complications.
Overdose-context constraints No specific antidote is known for this overdose.

Resulting Overdose Structure

Official overdose statements:

  • Overdose presents with a mix of CNS depression and excitation; the excitation phase, including seizures, is documented as prominent in children.
  • The profile includes serious cardiovascular risks like arrhythmias and hypotension, along with rhabdomyolysis.
  • Immediate medical attention is the mandated action for suspected overdose, particularly when severe symptoms are present.
  • Management is strictly symptomatic and supportive, requiring hospital monitoring of vital signs and heart activity.

Connection to the overall overdose profile: Regulatory documents define the official overdose profile by documenting the potential for life-threatening complications and the absence of a specific reversal agent. This necessitates the strict instruction to seek immediate medical attention for all suspected cases. The officially documented spectrum of CNS and cardiac toxicity requires hospital monitoring and management via symptomatic and supportive treatment to address the formally documented manifestations.

Therapeutic Uses of Codryl

What Codryl Treats: Main Uses and Benefits

Codryl is used across therapeutic domains to provide additional symptomatic support for upper respiratory conditions and common cold episodes. The medicine is considered relevant for managing symptom clusters that may appear suddenly and interfere with daily comfort. The key active ingredients in this formulation are commonly used to help relieve irritant cold and allergy symptoms, including cough.

Comprehensive Symptomatic Relief

The medication is commonly used to help manage the pattern where the patient experiences symptoms related to heightened physiological activity. It is applied in addressing two specific symptoms: the urge of a persistent, dry cough, and the burden of thick secretions in the throat and chest. Codryl helps address symptom clusters that may become intense or disruptive, including sneezing, runny nose (rhinorrhea), and discomfort like watery or itchy eyes and throat.

“The combination is used to support patients during difficult episodes by easing the overall symptom load associated with a chesty cold.”

The main indications where this product is relevant include conditions characterized by periods of heightened symptoms such as acute cold episodes, seasonal discomfort, and situations requiring short-term relief from an irritating cough and chest congestion. Providing support that helps ease the overall symptom burden contributes to general well-being during symptomatic phases.

Quick Fact: Support for Dual Symptom Patterns
Codryl is relevant when the patient needs support for managing both an irritating cough and thick secretions simultaneously.

Eligibility and Restrictions for Use

Official Population Eligibility for Codryl

Codryl is formally eligible for use by adults and adolescents (12 years and older) who do not have documented contraindications. Regulatory labeling defines strict population-based rules regarding who must not use the medicine and who requires limited or conditional use.

Contraindicated Populations (Must Not Use)

The medicine is strictly contraindicated in several groups. This absolute non-eligibility includes children under 6 years of age and breastfeeding mothers. Patients with severe hepatic (liver) impairment, narrow-angle glaucoma, or pyloroduodenal obstruction are prohibited from use. Codryl must also not be used by individuals with conditions causing urinary retention or those who have taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Restricted and Conditional Use

Use requires extreme caution in older adults (65+ years) due to heightened susceptibility to adverse effects. Conditional use is specified for individuals with moderate hepatic or renal (kidney) impairment. The medicine is generally not recommended during pregnancy.

What should I know about interactions with other medicines?

The interaction profile of Codryl is structured around the two active components, encompassing both pharmacodynamic reinforcement and pharmacokinetic alteration.

Official Interaction Statements

Classification Interacting Agents / Classes Official Interaction Outcome Timing / Condition
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Prolong and intensify the anticholinergic (drying) effects of the antihistamine component. Prohibited use within 14 days of stopping MAOIs.
Additive Effect Alcohol (Ethanol); Other CNS Depressants (e.g., hypnotics, sedatives, tranquilizers) Additive effects on the central nervous system, enhancing sedation. Use with caution officially indicated.
Exposure Alteration Basic Drugs (e.g., Amphetamine, Methamphetamine, Pseudoephedrine) Ammonium chloride increases their renal clearance, officially decreasing plasma levels and therapeutic effects. pH-dependent pharmacokinetic effect.
Additive Toxicity Dichlorphenamide; Spironolactone Risk of systemic acidosis by pharmacodynamic synergism. Use with caution officially indicated.

Population-Specific Interaction Notes

Interaction risk is officially higher in certain patient populations. The product is contraindicated in cases of severe hepatic dysfunction or severe renal impairment due to the enhanced risk of toxicity from the Ammonium Chloride component. Furthermore, elderly patients are officially noted to be more susceptible to additive effects, such as dizziness and sedation, when the antihistamine component is co-administered with other CNS depressants.

Connection to the overall interaction profile

Regulatory documents define this product's interaction structure based on the pharmacodynamic effects of Diphenhydramine and the pharmacokinetic effect of Ammonium Chloride. The profile specifies both absolute contraindications (MAOIs) and clinically significant exposure-modifying interactions to guide regulatory constraints.

Mechanism of Action

Codryl, an aggregate pharmaceutical composition, exerts its effects through four distinct pharmacodynamic mechanisms on the respiratory system.

Terbutaline acts as a selective agonist at beta2-adrenergic receptors primarily located on the smooth muscle cells of the bronchial tree. This interaction initiates the G-protein coupled receptor (GPCR) cascade, leading to the activation of adenylyl cyclase, increased intracellular levels of cyclic adenosine monophosphate (cAMP), and subsequent activation of protein kinase A (PKA). PKA-mediated phosphorylation results in the decreased intracellular concentration of calcium ions, promoting the relaxation of airway smooth muscle. This induces bronchodilation, facilitating enhanced airflow.

Bromhexine functions as a mucolytic agent by targeting glandular cells within the respiratory mucosa. It works to depolymerize mucopolysaccharide fibers and activate sialyltransferases, leading to the hydrolysis of mucoproteins and a decrease in mucus viscosity. Simultaneously, it stimulates the activity of serous glands, increasing the volume and reducing the stickiness of the airway secretions.

Guaifenesin acts as an expectorant, primarily through a reflex mechanism that irritates the gastric vagal receptors. This signals the parasympathetic centers in the medulla, resulting in an enhanced volume of thinner, less viscous fluid secretion by the respiratory tract glands. This aids in the hydration and expulsion of tracheobronchial secretions.

Menthol operates through local sensory nerve endings, likely involving the transient receptor potential melastatin 8 (TRPM8) channel, a cold receptor agonist. This interaction induces a local, non-systemic sensation.

Dosage and Administration Information

Codryl is administered via the oral route as a liquid solution, which typically contains 12.5 mg of Diphenhydramine hydrochloride per 5 mL. Established parameters for use include an emphasis on accurate measurement and defined frequency patterns.


Standard Administration Guidelines

The administration of Codryl is governed by standardized parameters for dosing and scheduling. For adults, the standard single dose of Diphenhydramine HCl is 25 mg to 50 mg, corresponding to 10 mL to 20 mL of the solution. This dose is taken every 4 to 6 hours as needed for symptomatic relief. A strict limit dictates that no more than six doses may be administered within any 24-hour period.


Procedural and Population Rules

Procedural Rule Description
Measurement The liquid must be measured using a calibrated device (e.g., dosing cup or syringe); household spoons are not appropriate for ensuring the correct dose volume.
Food Relation The medicine may be administered with or without food.
Age-Specific Dosing Lower initial doses should be considered for older adults. For pediatric patients aged 6 to 11 years, a reduced single dose of 12.5 mg to 25 mg is indicated, not to exceed 150 mg in 24 hours.
Missed Dose If a scheduled administration is missed, the dose should be skipped if it is near the next dose time; double dosing is not permitted.

The medicine is designated for short-term, symptomatic use only, and its procedural structure ensures adherence to limits on total daily exposure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Codryl

This overview describes what types of research have been conducted on the components of Codryl, what has been measured in those studies, and what researchers say remains uncertain. This is a descriptive summary of the evidence landscape and is not clinical advice.


Evidence for Relief of Acute Cough Associated with the Common Cold

Short-term Randomized Controlled Trials (RCTs) have been used in research evaluating the components of medicines like Codryl, which include an antitussive and an expectorant. These studies were used in research exploring how symptoms change over time in adults who have an acute cough lasting only a few days due to a common cold. Researchers examined patient-reported outcomes describing perceived discomfort, such as how often the person coughed during the day and at night, and how severe their cough felt. Data show patterns related to the widely studied properties of the cough suppressant component, Diphenhydramine. However, regulatory reviews noted that findings were mixed regarding whether the specific fixed-dose combination was conclusively better than a placebo (a sugar pill) at all measured time points.

Studies on the Combination's Dual Action

Studies were designed to examine the measured outcomes associated with the two main components of Codryl. Evidence is available regarding the component classified as an antitussive by regulatory bodies. In contrast, the clinical contribution of the expectorant component (Ammonium chloride) for acute cough in humans is often described as having limited information for long-term outcomes in high-quality trials, and some systematic reviews noted that data for its efficacy are still emerging.


What Remains Uncertain About the Research for Codryl

The overall evidence landscape for this fixed-dose combination highlights several areas where further data or consistent findings are needed:

  • Clinical Efficacy of the Expectorant: There is a lack of consistent, high-quality RCT data exploring the measured outcomes of the Ammonium chloride component in helping patients clear phlegm during an acute cold episode.
  • Comparative Evidence: Comparative evidence is lacking regarding the contribution of the specific combination when compared to simpler treatments.
  • Long-Term Outcomes: The research primarily addresses short-term relief (typically 4–7 days), with limited information for long-term outcomes or data on use over an extended period.

Key Studies & References Diphenhydramine NIH MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Codryl (FAQ)

Q: How quickly should I expect Codryl to start working?

According to official product information, the primary ingredient, diphenhydramine, is quickly absorbed into the body. Studies indicate that the medicine's maximum activity level is generally reached in approximately one hour after administration.

Q: Does Codryl interact with common over-the-counter pain relievers?

Official guidance on the diphenhydramine component indicates that it is described as generally having no known interactions with common over-the-counter pain relievers. This includes non-prescription medicines such as ibuprofen or paracetamol.

Q: Is Codryl safe to use while taking dietary supplements like melatonin?

Information from regulatory databases suggests that using this medicine alongside supplements like melatonin is associated with a potential for increased side effects. These increased effects include symptoms like dizziness, confusion, or drowsiness.

Q: How long does Codryl usually remain in a person's system after the last dose?

Regulatory data describes the elimination half-life of the diphenhydramine component. This half-life, which relates to how long a substance stays in the system, is approximately 9 hours in adults, usually ranging from 7 to 12 hours.

Q: What are the signs of a severe allergic reaction to Codryl?

Official documents describe that signs of a severe allergic reaction, such as anaphylaxis, may include specific symptoms. Symptoms described may include difficulty breathing, wheezing, or swelling of the face, lips, or tongue.

Q: Can Codryl affect fertility in men or women?

Research examining the diphenhydramine component in animal studies has been reviewed by regulatory bodies. These studies did not reveal evidence of impaired fertility in the animals tested.

Q: What are the known interactions between Codryl and birth control pills?

When checked against standard interaction databases, the diphenhydramine component typically shows no reported interactions with common hormonal birth control medicines. This is based on reviewing common components like levonorgestrel.

Q: Is Codryl ever used in combination with other similar drugs?

The Ammonium chloride component is noted for pharmacodynamic interactions with certain other drugs. These are medicines that affect levels of serum potassium or acidosis in the body, which regulatory constraints require caution is required.

Q: Do Codryl side effects usually lessen over time?

Official safety constraints note that the sedative effects are generally most prominent when first starting the treatment. Official information does not contain a general statement that applies to all possible side effects.

Q: What organs in the body could be affected by Codryl, according to official warnings?

Regulatory warnings and adverse reaction reports indicate documented effects on multiple body systems. These can include the nervous system, gastrointestinal system, cardiac (heart) system, and urinary system.

Q: Are there specific foods or beverages that interact with Codryl?

Official interaction statements specifically include a warning about alcohol due to the risk of enhanced sedation. Specific warnings regarding common foods are generally not listed in official regulatory documents.

Q: Why do some people report feeling lightheaded after starting Codryl?

Lightheadedness has been associated with the medicine's documented side effects of dizziness and hypotension. Hypotension is the clinical term for low blood pressure, which can sometimes result in a lightheaded feeling.

Q: Why is Codryl only available by prescription?

Official documents classify Codryl as an Antihistamine-Expectorant combination that is commonly classified by regulatory bodies as available over-the-counter (OTC) for the relief of cough and cold symptoms. Different formulations or local regulatory classifications may account for a prescription requirement.

Q: Do studies suggest Codryl can affect a person's mood or mental health?

Official labeling notes documented effects on the nervous system. These can include excitation, confusion, or disturbed attention.

Q: How is Codryl described in official documents regarding its mechanism of action?

Regulatory information describes the dual mechanism of action. The diphenhydramine component acts as an antihistamine to relieve cold symptoms and suppress cough, while the Ammonium chloride component functions as an expectorant, helping to clear respiratory secretions.

Q: What are the typical patient expectations for improvement when starting Codryl?

The medicine is designated for short-term, symptomatic relief of acute cough and cold discomfort. The onset of maximum activity for the antihistamine component is generally expected within about one hour.

Q: Does Codryl cause any known problems with driving or operating machinery?

Official safety warnings advise that the medication may cause side effects like dizziness or drowsiness. For this reason, official labeling includes a warning against driving or operating machinery.

Q: What is the maximum duration of use for Codryl described in clinical guidelines?

The medicine is designated for short-term, symptomatic use only, according to official procedural rules. Clinical guidelines advise that use be discontinued if symptoms persist or worsen beyond a brief period.

Q: Do studies exist that examine the effect of Codryl on sleep quality?

The diphenhydramine component is widely studied and is often included in products officially labeled as a nighttime sleep-aid. This use is based on its known sedative effects.

How should Codryl be stored and disposed of?

How to Store and Dispose of Codryl?

Regulatory documentation mandates specific conditions to maintain the stability of Codryl oral liquid and ensure safety.


Required Storage and Handling

Codryl must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be protected from light, excess heat, and freezing. Keep the liquid in the original container, ensure it is tightly closed, and store it in a dry place (not a bathroom). It is mandatory to keep the product out of the sight and reach of children and pets at all times.


Official Disposal Instructions

Unused or expired Codryl must be disposed of according to local regulations. The preferred method is using a drug take-back program. It is prohibited to dispose of the medicine by flushing it down a toilet or pouring it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Codryl found in:

A-Z Index: